Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis

British Journal of Haematology

Volumn 173, Issue 6, 2016, Pages 938-940

  Guglielmelli, Paola ^a   Rotunno, Giada ^a   Bogani, Costanza ^a   Mannarelli, Carmela ^a   Giunti, Laura ^b   Provenzano, Aldesia ^b   Giglio, Sabrina ^b   Squires, Matthew ^c   Stalbovskaya, Viktoriya ^c   Gopalakrishna, Prashanth ^c   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CALR; JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; ruxolitinib

Indexed keywords

CALRETICULIN; JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB;

ALLELE; ANEMIA; CALR GENE; CAPILLARY ELECTROPHORESIS; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME INHIBITION; FOLLOW UP; GENE MUTATION; HUMAN; LETTER; MORTALITY RISK; MYELOFIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK REDUCTION; SPLEEN SIZE; SPLENECTOMY; SPLENOMEGALY; SYMPTOM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84973644423     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13644     Document Type: Letter

References (10)

1. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895–2901.
2. Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R.S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C.N., Knoops, L. & Gisslinger, H.; COMFORT-II investigators. (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 122, 4047–4053.
3. Guglielmelli, P., Biamonte, F., Rotunno, G., Artusi, V., Artuso, L., Bernardis, I., Tenedini, E., Pieri, L., Paoli, C., Mannarelli, C., Fjerza, R., Rumi, E., Stalbovskaya, V., Squires, M., Cazzola, M., Manfredini, R., Harrison, C., Tagliafico, E. & Vannucchi, A.M.; on behalf of the COMFORT-II Investigators and the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. (2014) Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 123, 2157–2160.
4. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787–798.
5. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schonegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. & Kralovics, R. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England Journal of Medicine, 369, 2379–2390.
6. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.Q., Greaves, M., Bowen, D., Huntly, B.J., Harrison, C.N., Cross, N.C., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. & Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. The New England Journal of Medicine, 369, 2391–2405.
7. Passamonti, F., Caramazza, D. & Maffioli, M. (2014) JAK inhibitor in CALR-mutant myelofibrosis. The New England Journal of Medicine, 370, 1168–1169.
8. Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martinez-Trillos, A., Casetti, I., Colomer, D., Pieri, L., Pratcorona, M., Rotunno, G., Sant'Antonio, E., Bellini, M., Cavalloni, C., Mannarelli, C., Milanesi, C., Boveri, E., Ferretti, V., Astori, C., Rosti, V., Cervantes, F., Barosi, G., Vannucchi, A.M. & Cazzola, M. (2014) Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis. Blood, 124, 1062–1069.
9. Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 188, 1723–1735.
10. Vannucchi, A.M., Lasho, T.L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., Ketterling, R.P., Rotunno, G., Knudson, R.A., Chiara Susini, M., Laborde, R.R., Spolverini, A., Pancrazzi, A., Pieri, L., Manfredini, R., Tagliafico, E., Zini, R., Jones, A., Zoi, K., Reiter, A., Duncombe, A., Pietra, D., Rumi, E., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C. & Tefferi, A. (2013) Mutations and prognosis in primary myelofibrosis. Leukemia, 27, 1861–1869.